實(shí)驗(yàn)和臨床精神藥理學(xué)旨在促進(jìn)精神藥理學(xué)學(xué)科的最大多樣性。心理藥理學(xué)必然涉及行為變化、心理過(guò)程或其生理底物作為一個(gè)中心變量，心理藥理學(xué)藥物作為第二個(gè)中心變量。這些藥劑包括在工作場(chǎng)所或環(huán)境中遇到的藥物、藥物和化學(xué)品。該雜志的一個(gè)目標(biāo)是促進(jìn)基礎(chǔ)研究和心理藥理學(xué)理論的發(fā)展。另一個(gè)是鼓勵(lì)基礎(chǔ)研究和應(yīng)用研究相結(jié)合，開(kāi)發(fā)更好的藥物濫用治療方法，以及更有效的藥物治療。為此，該雜志發(fā)表了涉及動(dòng)物或人類的原始實(shí)驗(yàn)研究，涵蓋（a）社會(huì)、行為、認(rèn)知、情感、生理和神經(jīng)化學(xué)毒性的行為藥理學(xué)研究；（b）藥物濫用的描述性和實(shí)驗(yàn)研究，包括其病因、進(jìn)展、不良反應(yīng)和行為和藥物治療；（c）對(duì)照臨床試驗(yàn)，除了提高有效性、應(yīng)用范圍或深度外，還將增加我們對(duì)心理功能或藥物調(diào)節(jié)的理解。該雜志還發(fā)表了理論和綜合分析和評(píng)論，以促進(jìn)我們的理解和進(jìn)一步的心理藥理學(xué)系統(tǒng)研究。該雜志還出版了其他兩個(gè)部分的論文：創(chuàng)新和評(píng)論。創(chuàng)新是一個(gè)偶然的部分，它將強(qiáng)調(diào)建立一種新方法、新結(jié)果、新措施或新理論的論文。可以征求評(píng)論來(lái)說(shuō)明創(chuàng)新的性質(zhì)，并提供對(duì)比意見(jiàn)。評(píng)論是另一個(gè)偶然的部分。“評(píng)論”的目的是對(duì)該領(lǐng)域的重要方面進(jìn)行簡(jiǎn)短的評(píng)論，而這些方面此前尚未得到討論或考慮。評(píng)論可以解決經(jīng)驗(yàn)或理論問(wèn)題。預(yù)計(jì)發(fā)言將是博學(xué)的、綜合的、實(shí)質(zhì)性的和深思熟慮的。雖然案例研究不合適，但偶爾也可以考慮對(duì)特殊人群進(jìn)行小樣本實(shí)驗(yàn)。該雜志旨在為基礎(chǔ)和應(yīng)用研究人員以及在不同環(huán)境下工作的從業(yè)者提供信息和有用。實(shí)驗(yàn)和臨床精神藥理學(xué)尋求成為最佳研究思想和整合藥理學(xué)和行為的載體。

Experimental and Clinical Psychopharmacology seeks to promote the discipline of psychopharmacology in its fullest diversity. Psychopharmacology necessarily involves behavioral change, psychological processes, or their physiological substrates as one central variable and psychopharmacological agents as a second central variable. Such agents will include drugs, medications, and chemicals encountered in the workplace or environment. One goal of the journal is to foster basic research and the development of theory in psychopharmacology. Another is to encourage the integration of basic and applied research, the development of better treatments for drug abuse, and more effective pharmacotherapeutics. To this end, the journal publishes original empirical research involving animals or humans that spans (a) behavioral pharmacology research on social, behavioral, cognitive, emotional, physiological, and neurochemical toxicity; (b) descriptive and experimental studies of drug abuse, including its etiology, progression, adverse effects, and behavioral and pharmacological treatment; and (c) controlled clinical trials that, in addition to improving the effectiveness, range, or depth of application, will increase our understanding of psychological functions or their drug modulation. The journal also publishes theoretical and integrative analyses and reviews that promote our understanding and further systematic research in psychopharmacology. The journal also publishes papers in two other sections, Innovations and Remarks. Innovations is an occasional section that will highlight papers that establish a novel method, a novel result, a novel measure, or a new theory. Commentary may be solicited to address the nature of the innovation and to provide contrasting views. Remarks is another occasional section. The purpose of "remarks" is for brief commentary about important aspects of the field that have not been previously addressed or considered. Remarks could address either empirical or theoretical issues. Remarks are expected to be erudite, integrative, substantive, and thoughtful. Although case studies are not appropriate, occasional small sample experiments with special populations may be considered. The journal is intended to be informative and useful to both basic and applied researchers and to practitioners operating in varied settings. Experimental and Clinical Psychopharmacology seeks to be the vehicle for the best research ideas and for integrating pharmacology and behavior.